For your appropriate hypertensive patients turn to TEKTURNA HCT—proven BP reductions in mild-to-moderate hypertension1,2

The primary endpoint was change in msDBP from baseline to week 8.

Change from baseline in msSBP (mm Hg)

  • Tekturna HCT
    150/12.5 mg

    -18

  • Tekturna HCT
    150/25 mg

    -20

  • Tekturna HCT
    300/12.5 mg

    -20

  • Tekturna HCT
    300/25 mg

    -21

Mean baseline SBP 153-155 mm Hg (TEKTURNA HCT)
Least square means (LSM) change from baseline in msSBP (mm Hg)

Mean non-placebo–subtracted DBP in study (mm Hg).

Change from baseline in msDBP (mm Hg)

  • Tekturna HCT
    150/12.5 mg

    -12

  • Tekturna HCT
    150/25 mg

    -13

  • Tekturna HCT
    300/12.5 mg

    -14

  • Tekturna HCT
    300/25 mg

    -14

Mean baseline DBP 153-155 mm Hg (TEKTURNA HCT)
Least square means (LSM) change from baseline in msDBP (mm Hg)

Mean non-placebo–subtracted DBP in study (mm Hg).

Study design

TEKTURNA HCT was studied in an 8-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, multifactorial study in patients with mild-to-moderate hypertension (msDBP 95-109 mm Hg). The mean baseline SBP/DBP range was 153-155/99-100 mm Hg. The primary endpoint in this trial was change in msDBP from baseline to week 8.

Turn to TEKTURNA HCT

  • As initial therapy in patients likely to need multiple drugs to achieve BP goals2
  • For patients whose BP is not adequately controlled with aliskiren or hydrochlorothiazide (HCTZ) monotherapy2

Patients with BP ≥160/100 (formerly stage 2 hypertension)

For your appropriate hypertensive patients turn to TEKTURNA for BP ≥160/100 (formerly stage 2 hypertension)3

TEKTURNA HCT: proven BP reductions in patients with BP ≥160/100 (formerly stage 2 hypertension)3

  • TEKTURNA HCT (N=346)
    300/25 mg

    -30

Baseline msSBP 167 mm Hg*
Least square means (LSM) change from baseline in msSBP (mm Hg) at primary endpoint

Efficacy was compared with aliskiren 300 mg (n=335), which achieved msSBP reductions of -20 mm Hg at week 12.

*Patients with stage 2 hypertension.

Study design

A 12-week, double-blind, randomized, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared with aliskiren 300 mg in patients with BP ≥160/100 (formerly stage 2 hypertension). The primary efficacy variable was the change from baseline (visit 2/day 1) in msSBP at endpoint. For each patient, the last postbaseline measurement during the double-blind period was carried forward to week 12 as the endpoint measurement.3

At week 12, change from baseline in msDBP was -8 mm Hg for aliskiren 300 mg and -13 mm Hg for aliskiren 300 mg and hydrochlorothiazide 25 mg.3

TEKTURNA HCT safety profile: extensively studied in more than 2700 patients2

Common adverse events (AEs) with TEKTURNA HCT vs placebo2

AE TEKTURNA HCT Placebo
Dizziness 2.3% 1.0%
Influenza 2.3% 1.6%
Diarrhea 1.6% 0.5%
Cough 1.3% 0.5%
Vertigo 1.2% 0.5%
Asthenia 1.2% 0%
Arthralgia 1.0% 0.5%

*At 300 mg.
†Does not include AEs from the ALTITUDE study.

TEKTURNA HCT discontinuation rates due to AEs less than placebo

  • 2.7% of study population for TEKTURNA HCT vs 3.6% on placebo

TEKTURNA HCT is available in 4 dosage strengths

TEKTURNA HCT dosing considerations

  • TEKTURNA HCT is dosed once daily2

    • The usual recommended starting dose is 150/12.5 mg once daily as needed to control BP
    • The dose may be titrated up to a maximum dose of 300/25 mg

  • Patients should take TEKTURNA HCT at the same time every day2

    • TEKTURNA HCT can be taken with or without food
    • Patients should establish a routine for taking TEKTURNA HCT with meals

Antihypertensive effect largely manifested within 1 week. Maximal effects generally seen at ≈4 weeks.2

References: 1. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25(1):217-226. 2. Tekturna HCT [prescribing information]. Boston, MA: Noden Pharma USA Inc; 2016. 3. Data on file. Clinical study report 2353. Novartis Pharmaceuticals Corp.